Seaport Therapeutics

SPTX · Nasdaq · United States

Share price · SPTX

$18.31-5.66 (-23.61%) 3M

close as of 2026-11-18 · 24h delayed · vol 684K (2.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SPTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Sep 2026-8.7%

    Nothing announced by SPTX that day or the session before.

  2. 26 Aug 2026+12.1%

    Nothing announced by SPTX that day or the session before.

  3. 8 Jul 2026+16.6%

Share of unusual movement by asset

For each asset, the share of SPTX's own-move activity since 4 May 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
GlyphAllo (allopregnanolone prodrug) (SPT-300)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—77%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
GABA-A receptorSmall molecule
Major Depressive Disorder

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
GlyphAllo (allopregnanolone prodrug) · SPT-300Phase 2Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Est. primary completion 2027-03 · NCT07065240 · CT.gov ↗
What to watch
May 2027 (1)
GlyphAllo (allopregnanolone prodrug) · SPT-300Phase 2Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
Est. primary completion 2027-05 · NCT07161700 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 September 2026Topline resultGlyphAllo (allopregnanolone prodrug)Phase 1 driving simulation trial of GlyphAllo met its primary endpoint
Seaport Therapeutics · Source ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$24M$62M+ $229M short-term inv.$26M-$23M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$25M$64M+ $209M short-term inv.$63M-$26M operating cash flowreport ↗
2026-Q1—$21M$53M+ $130M short-term inv.$25M-$20M operating cash flowreport ↗
2025-Q3—$20M—$23M-$16M operating cash flowreport ↗
2025-Q2—$13M—$15M-$15M operating cash flowreport ↗
2025-Q1—$11M—$13M-$20M operating cash flowreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$46M+ $170M short-term inv.—report ↗

Seaport Therapeutics reported cash and equivalents of $46.04M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($20.1M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-10Zohar Daphne · director, Chief Executive OfficerGift100,000——Form 4
2026-11-03Torres Denice · directorOpen-market purchase5,000$19.86$99KForm 4
2026-06-22HOMBACH ROBERT J. · directorOpen-market purchase13,000$18.14$236KForm 4
2026-05-04PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% ownerConversion12,736,014——Form 4
2026-05-04PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% ownerConversion2,681,265——Form 4
2026-05-04PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% ownerConversion965,255——Form 4
2026-05-04PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% ownerConversion (derivative)40,000,000——Form 4
2026-05-04PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% ownerConversion (derivative)8,421,052——Form 4